Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Encouraging doctors to work as a team on data development and patient care could be one way to improve the condition of stressed GPs, according to a new study.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer
2.
More People Than Previously Believed Have Schizophrenia.
3.
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer
4.
Novel Agent for Chronic GVHD Wins FDA Approval
5.
Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?
1.
Clinical Pharmacology of Stromal-Targeted Anticancer Pharmacotherapy
2.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
3.
Metabolic Heterogeneity and Tumor Persistence: Mechanisms, Clinical Implications, and Emerging Strategies
4.
Strategic Standards in Hematology for Specialists
5.
Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge